Valeant Pharmaceuticals International, Inc. (VRX) Lowered to Hold at Vetr Inc.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) was downgraded by equities researchers at Vetr from a “strong-buy” rating to a “hold” rating in a note issued to investors on Friday. They presently have a $14.26 target price on the specialty pharmaceutical company’s stock. Vetr‘s price target suggests a potential upside of 3.11% from the company’s current price.

A number of other research firms also recently weighed in on VRX. Zacks Investment Research downgraded Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a report on Thursday. Stifel Nicolaus reaffirmed a “buy” rating and set a $35.00 price objective on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. BidaskClub raised Valeant Pharmaceuticals International from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Piper Jaffray Companies reaffirmed a “sell” rating and set a $14.00 price objective on shares of Valeant Pharmaceuticals International in a report on Sunday, September 17th. Finally, Cantor Fitzgerald set a $23.00 price objective on Valeant Pharmaceuticals International and gave the company a “buy” rating in a report on Wednesday, August 16th. Five investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $17.71.

Shares of Valeant Pharmaceuticals International (VRX) opened at 13.83 on Friday. Valeant Pharmaceuticals International has a 12 month low of $8.31 and a 12 month high of $24.30. The stock’s 50 day moving average price is $14.00 and its 200-day moving average price is $13.52. The firm’s market capitalization is $4.82 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.97 by $0.08. The company had revenue of $2.23 billion for the quarter, compared to the consensus estimate of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The company’s quarterly revenue was down 7.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.88) earnings per share. On average, equities analysts anticipate that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://sportsperspectives.com/2017/10/13/valeant-pharmaceuticals-international-inc-vrx-lowered-to-hold-at-vetr-inc.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De bought 10,000 shares of the company’s stock in a transaction on Monday, August 21st. The stock was bought at an average price of $14.33 per share, for a total transaction of $143,300.00. Following the transaction, the director now owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 5.87% of the company’s stock.

Institutional investors have recently modified their holdings of the business. ValueAct Holdings L.P. grew its holdings in shares of Valeant Pharmaceuticals International by 20.0% in the 1st quarter. ValueAct Holdings L.P. now owns 17,997,224 shares of the specialty pharmaceutical company’s stock valued at $198,509,000 after buying an additional 3,002,963 shares during the period. Paulson & CO. Inc. grew its holdings in shares of Valeant Pharmaceuticals International by 12.5% in the 2nd quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock valued at $377,372,000 after buying an additional 2,428,900 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Valeant Pharmaceuticals International in the 2nd quarter valued at $41,574,000. Canada Pension Plan Investment Board grew its holdings in shares of Valeant Pharmaceuticals International by 24,953.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 2,104,500 shares of the specialty pharmaceutical company’s stock valued at $36,525,000 after buying an additional 2,096,100 shares during the period. Finally, Cannell Peter B & Co. Inc. acquired a new position in shares of Valeant Pharmaceuticals International in the 2nd quarter valued at $20,981,000. Institutional investors own 50.48% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply